Cell size and invasion in TGF-β–induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway

Samy Lamouille, Rik Derynck

The Journal of Cell Biology · 2007 · 565 citations · 28 references

DOIFull text

Open access

Concepts

TL;DR

Epithelial‑to‑mesenchymal transition promotes cancer metastasis by enhancing cell motility and invasion, and TGF‑β drives EMT through Smad‑dependent transcription, non‑Smad signaling, and a translational arm mediated by mTOR that complements the Smad pathway. TGF‑β activates mTOR via PI3K/Akt, which phosphorylates S6K1 and eIF4E‑binding protein 1 to up‑regulate translation initiation. TGF‑β increases cell size and protein content during EMT, rapamycin blocks this mTOR‑dependent translation and size gain without affecting EMT, and rapamycin also diminishes the migratory and invasive behavior associated with TGF‑β‑induced EMT, highlighting mTOR as a therapeutic target.

Abstract

Epithelial to mesenchymal transition (EMT) occurs during development and cancer progression to metastasis and results in enhanced cell motility and invasion. Transforming growth factor-β (TGF-β) induces EMT through Smads, leading to transcriptional regulation, and through non-Smad pathways. We observe that TGF-β induces increased cell size and protein content during EMT. This translational regulation results from activation by TGF-β of mammalian target of rapamycin (mTOR) through phosphatidylinositol 3-kinase and Akt, leading to the phosphorylation of S6 kinase 1 and eukaryotic initiation factor 4E–binding protein 1, which are direct regulators of translation initiation. Rapamycin, a specific inhibitor of mTOR complex 1, inhibits the TGF-β–induced translation pathway and increase in cell size without affecting the EMT phenotype. Additionally, rapamycin decreases the migratory and invasive behavior of cells that accompany TGF-β–induced EMT. The TGF-β–induced translation pathway through mTOR complements the transcription pathway through Smads. Activation of mTOR by TGF-β, which leads to increased cell size and invasion, adds to the role of TGF-β–induced EMT in cancer progression and may represent a therapeutic opportunity for rapamycin analogues in cancer.

References

28